Boehringer Ingelheim, a leader in developing treatments for lung diseases, sponsored a phase 2 clinical trial investigating four doses of BIBF 1120 (nintedanib) in patients with idiopathic pulmonary fibrosis. The primary goal of “Safety…
In a recent study entitled “Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis,” a team of researchers show acute exacerbations in idiopathic pulmonary fibrosis are caused by multifactorial cellular responses, including macrophage activation. The study was published in the open access journal…
Pulmonary fibrosis may run in the family, based on the frequent occurrence of this disorder in people who are related, according to an article titled Familial Pulmonary Fibrosis recently published in Revue des Maladies Respiratoires by a group from the Centre de Compétence Maladies Rares Pulmonaires, Hôpital…
The European Commission (EC) has approved Boehringer Ingelheim‘s application for the commercialization of the drug nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF), within the European Union. Under the brand name Ofev, the drug therapy was approved by the EC due to…
A study published this week in The Journal of Molecular Medicine Reports discussed the discovery of biological mechanisms that may have important implications in the future treatment of idiopathic pulmonary fibrosis (IPF). The research was conducted by an international team of collaborating scientists from the University…
Lung Institute has announced the opening of a new clinic located in Scottsdale, Arizona this February, according to a press release. The new facility will become the institute’s third center to open in the United States that is focused on treatments using stem cells, joining a center in Tampa and in Nashville.
A new study entitled “PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis” discovered mitochondria PINK1 impaired expression underlies the formation of fibrotic tissue in older patients lungs. The study was published in The Journal of Clinical Investigation. Idiopathic pulmonary fibrosis (IPF) is…
Researchers in Ann Arbor Michigan and at Cornell University in New York have found that specific types of white blood cells (leukocytes) might be used to predict the disease progression of idiopathic pulmonary fibrosis (IPF). The study appeared in the December 22 issue of…
Columbia University Medical Center and Biogen Idec have established a strategic alliance worth $30 million focused on genetic research with the purpose of discovering underlying disease causes and new therapeutic options. The collaborative program is expected to broaden the knowledge of genomics and genome sequencing, as well as help patients who…
Clinical stage specialty pharmaceutical company Pacific Therpaeutics Ltd. has just obtained licensing for a drug technology that uses a rapid-acting oral disintegrating tablet (ODT), indicated for erectile dysfunction; and together with partner Montreal-based IntelGenx Corporation, a company focused on developing enhanced drug delivery systems, Pacific will be combining two already-approved…
Get regular updates to your inbox.
